SCHEMBL22728481

SCHEMBL22728481

Cc1ccc(-c2csc(NC(=O)c3ccc(C)cn3)n2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.64
KDM4E B2RXH2 4/20 0.64
NPC1 O15118 3/20 0.64
RAB9A P51151 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
MAPT P10636 7/20 0.62
HTT P42858 3/20 0.62
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
ALDH1A1 P00352 2/20 0.61
POLB P06746 2/20 0.61
ESR1 P03372 1/20 0.61
ESR2 Q92731 1/20 0.61
HSD17B10 Q99714 1/20 0.61
GSTO1 P78417 1/20 0.61
CDC25A P30304 1/20 0.58
CDC25B P30305 1/20 0.58
CDC25C P30307 1/20 0.58
THRB P10828 1/20 0.58
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26884355 0.90 KMT2A (0.66) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL22728480 0.88 MEN1 (0.59) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL22728498 0.86 LMNA (0.78) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL12248896 0.86 ADORA3 (0.68) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL22728476 0.85 LMNA (0.65) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL22728560 0.85 MEN1 (0.62) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL22728558 0.84 MPL (0.69) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL235190 0.83 KDM4E (0.70) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL22728458 0.83 MAPT (0.61) LMNAKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL24107408 0.82 LMNA (0.62) LMNAKDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2022-08-23 US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 WO disclosed
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2022-02-17 US disclosed
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2020-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 LMNA 4496/4885KDM4E 4225/4885NPC1 2133/4885
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder TNF, MSR1, GRN LMNA 1893/4885KDM4E 4725/4885NPC1 1571/4885
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN LMNA 1893/4885KDM4E 4725/4885NPC1 1571/4885
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN LMNA 1893/4885KDM4E 4725/4885NPC1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.